Multi-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer
Researchers can now reliably distinguish true cancer drivers from false alarms using patient tumors, helping oncologists select treatments that actually work for individual ovarian cancer patients.
A comprehensive multi-omics analysis of 335 HGSC patients found >40% harbor clinically relevant actionable alterations, but 58% of nominally pathogenic variants prove false positives without transcriptional support. NF1 deficiency emerged as the most common actionable driver, with patient-derived organoids demonstrating robust sensitivity to MEK inhibition, establishing a validated precision oncology workflow to distinguish true drivers from false positives.
What the study was
- Study design
- Multi-omics observational cohort (WGS+transcriptome, n=335 HGSC patients)
- Population
- 335 high-grade serous carcinoma (HGSC) patients
- Sample size
- 335
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Genome Med
Why it surfaced
Top-tier Genome Med study; integrated WGS+transcriptome in 335 HGSC patients reveals 58% false-positive rate for pathogenic variants and NF1 as key actionable target with organoid-validated drug sensitivity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.